Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
marketwatch.com
news
2022-06-03 11:14:24

Shares of Turning Point Therapeutics Inc. TPTX, +2.21% more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by biopharmaceutical company Bristol Myers Squibb Co. BMY, +0.15% in an all-cash deal valuing Turning Point at about $3.77 billion. Bristol Myers' stock was little changed ahead of the open. Under terms of the deal, Turning Point shareholders will receive $76.00 for each Turning Point share they own, representing a 122.5% premium to Thursday's closing price of $34.
